Baird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20
Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $14 to $20.
Login to comment